Seller record · Telehealth service

Spry

Fails 3 of 8 criteria. S3, pharmacy identification: No pharmacy is named on the home page, the product pages, the answers, the terms or the privacy policy. 2 more criteria also fail; see the table below.

At a glance

SpryTelehealth service

5/8criteria passed
Price
Semaglutide from $199, tirzepatide from $299
Sells
compounded semaglutide, compounded tirzepatide, BPC-157, and 2 more
FDA letters
None on file
Visit SprySee all eight dispositions

Telehealth service. Passes 5 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded semaglutide and tirzepatide with BPC-157, NAD+ and sermorelin at one printed price each, with a nurse practitioner reviewing each file. It names no filling pharmacy and gives a Clearwater, Florida address in its privacy policy.

Operating entity No legal entity name appears in the footer, on the contact page, in the terms or in the privacy policy, which name the company only as Spry.

Dispositions

CodeCriterionDispositionWhere it appears
S1Prescriber requirementPASSSpry's website; Spry's weight loss page
S2Prescription gatingPASSSpry's get started page; Spry's semaglutide product page
S3Pharmacy identificationFAILSpry's website; Spry's terms and conditions document
S4Compounding disclosureFAILSpry's weight loss page; Spry's semaglutide product page; Spry's tirzepatide product page
S5Analytical documentationFAILSpry's semaglutide product page; Spry's BPC-157 product page
S6Business addressPASSSpry's privacy policy document
S7Price disclosurePASSSpry's website; Spry's semaglutide product page; Spry's tirzepatide product page; Spry's BPC-157 product page
S8Enforcement statusPASSFDA warning-letter index

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed provider reviews each intake and writes the treatment plan, the answers say a nurse practitioner reviews each file within 24 hours before medication is ordered, and every medication is prescribed by a licensed provider.Source: Spry's website; Spry's weight loss page.
S2PASSThe start button opens an eligibility form whose first screen asks the buyer's current weight, goal weight and height.Source: Spry's get started page; Spry's semaglutide product page.
S3FAILNo pharmacy is named on the home page, the product pages, the answers, the terms or the privacy policy.Source: Spry's website; Spry's terms and conditions document.
S4FAILThe weight loss page calls the GLP-1 medications compounded, and no product page, answer or policy states that a compounded drug is not FDA-approved.Source: Spry's weight loss page; Spry's semaglutide product page; Spry's tirzepatide product page.
S5FAILNo certificate of analysis or lot document is published on the product pages or the policies.Source: Spry's semaglutide product page; Spry's BPC-157 product page.
S6PASSSpry at 600 Cleveland St. Ste 366, Clearwater, FL 33755, printed twice in the privacy policy.Source: Spry's privacy policy document.
S7PASSSemaglutide at $199, tirzepatide at $299, BPC-157 and sermorelin at $249 and NAD+ at $299, printed as starting prices on the home page and as the price on each product page, with no billing period stated beside them. The answers say the buyer is re-billed and the next vial shipped every 4 weeks.Source: Spry's website; Spry's semaglutide product page; Spry's tirzepatide product page; Spry's BPC-157 product page.
S8PASSNo FDA warning letter names Spry, and no action has halted the business.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, BPC-157, NAD+, sermorelin.

Visit Spry

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.